The Beneficial Role of Retinoids in Glomerular Disease

The primary etiology of CKD is a direct consequence of initial dysfunction and injury of the glomerulus, the main filtration system. Podocytes are terminally differentiated epithelial cells in the glomerulus, whose major function is the maintenance of this renal filtration barrier. Podocyte injury is implicated in many glomerular diseases including focal segmental glomerular sclerosis and HIV-associated nephropathy. In many of these diseased conditions, the podocyte can either undergo dedifferentiation and proliferation, apoptosis, or cell detachment. Regardless of the initial type of injury, the podocyte ultimately loses its functional capacity to maintain the glomerular filtration barrier. Significant injury resulting in a loss of the podocytes and failure to maintain the renal filtration barrier contributes to progressive kidney disease. Consequently, therapies that prevent podocyte injury and promote their regeneration will have a major clinical impact on glomerular disease. Retinoic acid (RA), which is a derivative of vitamin A, has many cellular functions including induction of cell differentiation, regulation of apoptosis, and inhibition of inflammation and proliferation. RA is required for kidney development and is essential for cellular differentiation in the setting of podocyte injury. The mechanism by which RA directs its beneficial effects is multifactorial, ranging from its anti-inflammatory and anti-fibrotic effects to a direct effect of upregulating podocyte differentiation markers in the podocyte. The focus of this review is to provide an overview of RA in kidney development and glomerular disease. We also highlight the key mechanism(s) by which RA restores podocyte differentiation markers and ameliorates glomerular disease.

[1]  M. Kitamura,et al.  Induction of nephrin gene expression by selective cooperation of the retinoic acid receptor and the vitamin D receptor. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  H. Gronemeyer,et al.  Molecular mechanisms of retinoid action. , 2001, Cellular & molecular biology letters.

[3]  P. Nelson,et al.  Retinoids Augment the Expression of Podocyte Proteins by Glomerular Parietal Epithelial Cells in Experimental Glomerular Disease , 2012, Nephron Experimental Nephrology.

[4]  P. Dollé,et al.  Retinoic acid in development: towards an integrated view , 2008, Nature Reviews Genetics.

[5]  T. B. Huber,et al.  Proteinuria impairs podocyte regeneration by sequestering retinoic acid. , 2013, Journal of the American Society of Nephrology : JASN.

[6]  V. D’Agati,et al.  HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. , 2000, Kidney international.

[7]  V. D’Agati,et al.  The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. , 1999, Journal of the American Society of Nephrology : JASN.

[8]  J. He,et al.  Induction of retinol dehydrogenase 9 expression in podocytes attenuates kidney injury. , 2014, Journal of the American Society of Nephrology : JASN.

[9]  J. He,et al.  Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure , 2011, Kidney international.

[10]  E. Ritz,et al.  Retinoid receptor-specific agonists alleviate experimental glomerulonephritis. , 2002, American journal of physiology. Renal physiology.

[11]  L. Barisoni,et al.  Current views on collapsing glomerulopathy. , 2008, Journal of the American Society of Nephrology : JASN.

[12]  S B Kaye,et al.  Retinoids: present role and future potential , 1999, British Journal of Cancer.

[13]  B. Smeets,et al.  Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells. , 2006, Kidney international.

[14]  B. Smeets,et al.  Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. , 2009, Journal of the American Society of Nephrology : JASN.

[15]  Martina I. Lefterova,et al.  Autoimmune Kidney Disease and Impaired Engulfment of Apoptotic Cells in Mice with Macrophage Peroxisome Proliferator-Activated Receptor γ or Retinoid X Receptor α Deficiency , 2011, The Journal of Immunology.

[16]  V. Yang,et al.  Mammalian Krüppel-like factors in health and diseases. , 2010, Physiological reviews.

[17]  C. M. Chen,et al.  Dominant effects of RET receptor misexpression and ligand-independent RET signaling on ureteric bud development. , 1999, Development.

[18]  N. Mongan,et al.  Diverse actions of retinoid receptors in cancer prevention and treatment. , 2007, Differentiation; research in biological diversity.

[19]  P. Chambon,et al.  Retinoic acid synthesis and hindbrain patterning in the mouse embryo. , 2000, Development.

[20]  Avi Ma’ayan,et al.  Krüppel-like Factor 15 (KLF15) Is a Key Regulator of Podocyte Differentiation* , 2012, The Journal of Biological Chemistry.

[21]  Matthias Kretzler,et al.  Comparative promoter analysis allows de novo identification of specialized cell junction-associated proteins. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Vilar,et al.  Role of retinoids in renal development: pathophysiological implication. , 1999, Current opinion in nephrology and hypertension.

[23]  A. Montpetit,et al.  A human ALDH1A2 gene variant is associated with increased newborn kidney size and serum retinoic acid. , 2010, Kidney international.

[24]  E. Ritz,et al.  Retinoic acid reduces glomerular injury in a rat model of glomerular damage. , 2000, Journal of the American Society of Nephrology : JASN.

[25]  E. Batourina,et al.  Vitamin A controls epithelial/mesenchymal interactions through Ret expression , 2001, Nature Genetics.

[26]  H. Gollnick,et al.  The retinoids. A review of their clinical pharmacology and therapeutic use. , 1987, Drugs.

[27]  E. Batourina,et al.  Stromal cells mediate retinoid-dependent functions essential for renal development. , 1999, Development.

[28]  M. Kitamura,et al.  Retinoids as a potential treatment for experimental puromycin‐induced nephrosis , 2003, British journal of pharmacology.

[29]  M. Kitamura,et al.  Retinoids in nephrology: promises and pitfalls. , 2004, Kidney international.

[30]  H. Kawachi,et al.  Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. , 2003, Journal of the American Society of Nephrology : JASN.

[31]  Yuji Nozaki,et al.  Retinoic Acid Reduces Autoimmune Renal Injury and Increases Survival in NZB/W F1 Mice , 2003, The Journal of Immunology.

[32]  Susana R. Neves,et al.  Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. , 2007, Journal of the American Society of Nephrology : JASN.

[33]  P. Chambon,et al.  Embryonic retinoic acid synthesis is essential for early mouse post-implantation development , 1999, Nature Genetics.

[34]  M. Hori,et al.  Therapeutic effect of all-trans retinoic acid on rats with anti-GBM antibody glomerulonephritis. , 2003, Kidney international.

[35]  Donald M. Steinwachs,et al.  Promises and pitfalls of the , 1997 .

[36]  Ravi Iyengar,et al.  Retinoic Acid Utilizes CREB and USF1 in a Transcriptional Feed-Forward Loop in Order To Stimulate MKP1 Expression in Human Immunodeficiency Virus-Infected Podocytes , 2008, Molecular and Cellular Biology.

[37]  Y. Matsuki,et al.  Role of Krüppel-like Factor 15 (KLF15) in Transcriptional Regulation of Adipogenesis* , 2005, Journal of Biological Chemistry.

[38]  G. Trinchieri,et al.  Retinoids Inhibit Interleukin-12 Production in Macrophages through Physical Associations of Retinoid X Receptor and NFκB* , 1999, The Journal of Biological Chemistry.

[39]  S. Shankland,et al.  ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. , 2005, Kidney international.

[40]  S. A N G-Y O U B H A N,et al.  Effect of retinoic acid in experimental diabetic nephropathy , 2004 .

[41]  Victoria Moreno-Manzano,et al.  Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. , 2004, Kidney international.

[42]  J. He,et al.  Novel Retinoic Acid Receptor Alpha Agonists for Treatment of Kidney Disease , 2011, PloS one.

[43]  Elisabeth Gerver,et al.  Promises and Pitfalls , 1986 .

[44]  V. D’Agati,et al.  Role of the retinoic acid receptor-α in HIV-associated nephropathy. , 2011, Kidney international.